Responses
Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR072/#1519 Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)
Compose a Response to This Article
Other responses
No responses have been published for this article.